Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Short-Term Debt & Capital Lease Obligation : $0.22 Mil (As of Nov. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Cannabis Bioscience International Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was $0.22 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Cannabis Bioscience International Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was $0.28 Mil.

Cannabis Bioscience International Holdings Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Cannabis Bioscience International Holdings's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Bioscience International Holdings Short-Term Debt & Capital Lease Obligation Chart

Cannabis Bioscience International Holdings Annual Data

Trend

Dec06

Dec07

May09

May10

May11

Short-Term Debt & Capital Lease Obligation

3.27

3.17

Cannabis Bioscience International Holdings Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	May09	Nov09	May10	Nov10	May11	Nov11	Nov22	Nov23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial							2.23	3.17	3.21	-	0.22

Cannabis Bioscience International Holdings Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cannabis Bioscience International Holdings Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036

Website

https://www.cbih.net

Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.